Zhejiang Jingxin Pharmaceutical Co., Ltd.

Equities

002020

CNE000001K73

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
11.41 CNY +0.44% Intraday chart for Zhejiang Jingxin Pharmaceutical Co., Ltd. +13.08% -10.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Evotec Says Partner Obtained Regulatory Approval in China for Insomnia Drug MT
Jingxin Pharmaceutical Gets Nod to Market Didacinil Capsules MT
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jingxin Pharma's Unit Gets Nod to Market Eye Drug in Europe MT
Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan, Payable on 24 May 2023 CI
ExoRNA Bio announced that it has received funding from Guangzhou Yuexiu Industrial Investment Fund Management Co., Ltd., Zhejiang Jingxin Pharmaceutical Co., Ltd., Dingxin Capital Co., Ltd., CDH Investment Management Company Limited and other investors CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces Directorate Appointments CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan, Payable on 25 May 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Approves 2021 Profit Distribution Plan At the Annual General Meeting Held on April 22, 2022 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces the Final Profit Distribution Proposal for 2021 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. signed an agreement to acquire Guangdong Shaxi Pharmaceutical Co., Ltd. from Jingxin Holding Group Co., Ltd. and Xinchang Yuanjin Health Industry Investment Partnership Enterprise (Limited Partnership) for approximately CNY 210 million. CI
Zhejiang Jingxin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Zhejiang Jingxin Pharmaceutical : Pharma Chairman Raises Stake to 35% in $77 Million Deal MT
Chart Zhejiang Jingxin Pharmaceutical Co., Ltd.
More charts
ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. is a China-based company engaged in manufacture of pharmaceuticals. The Company's pharmaceutical products include chemical pharmaceuticals, traditional medicines, biological agents and bulk pharmaceutical chemicals. Its pharmaceutical products are mainly applied in cardiovascular sector, digestive tract sector and psychoneural sector, among others. The Company is also engaged in the research and development, manufacture and sales of medical devices. Its medical devices include clinical displays, diagnosis displays, endoscopic surgery displays and ultrasonic image displays, among others. The Company operates its businesses in both domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
11.41
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002020 Stock
  4. News Zhejiang Jingxin Pharmaceutical Co., Ltd.
  5. Zhejiang Jingxin Pharmaceutical : Pharma Chairman Raises Stake to 35% in $77 Million Deal